drugset / Trial / NCT01239563
Thymoglobulin Induction in Kidney Transplant Recipients
Phase 3
Unknown
40 enrolled
University of Oxford
Genzyme, a Sanofi Company · collabOxford University Hospitals NHS Trust · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage that kidneys transplanted from deceased donors sustains on reperfusion.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 1.5 mg/kg | — |
| Subject | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 6 mg/kg | — |
| Comparator | Basiliximab | Monoclonal antibody | 20 mg | Intravenous |